A number of other analysts have also commented on the company. Stifel Nicolaus boosted their price objective on Masimo from $165.00 to $170.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. BTIG Research reissued a “hold” rating on shares of Masimo in a report on Thursday, August 1st. UBS Group boosted their price objective on Masimo from $172.00 to $180.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, ValuEngine lowered Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $159.25.
MASI stock opened at $145.99 on Tuesday. The stock’s 50 day simple moving average is $149.73 and its 200 day simple moving average is $144.68. Masimo has a fifty-two week low of $98.23 and a fifty-two week high of $160.25. The company has a market cap of $7.73 billion, a P/E ratio of 48.18, a price-to-earnings-growth ratio of 1.93 and a beta of 1.19.
Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.03. Masimo had a return on equity of 17.82% and a net margin of 22.15%. The business had revenue of $229.60 million for the quarter, compared to the consensus estimate of $222.46 million. During the same period in the prior year, the business earned $0.73 EPS. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. Equities analysts predict that Masimo will post 3.15 EPS for the current year.
In other news, EVP Yongsam Lee sold 1,078 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $152.42, for a total value of $164,308.76. Following the completion of the transaction, the executive vice president now directly owns 74,078 shares of the company’s stock, valued at $11,290,968.76. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Joe E. Kiani sold 18,437 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $160.02, for a total value of $2,950,288.74. Following the completion of the transaction, the chief executive officer now directly owns 157,678 shares of the company’s stock, valued at $25,231,633.56. The disclosure for this sale can be found here. Insiders have sold a total of 84,444 shares of company stock valued at $13,193,970 over the last three months. Corporate insiders own 11.50% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in MASI. Capital Investment Advisory Services LLC bought a new position in shares of Masimo in the second quarter valued at approximately $25,000. Financial Gravity Wealth Inc. bought a new position in shares of Masimo in the second quarter valued at approximately $31,000. Private Capital Group LLC grew its holdings in shares of Masimo by 92.1% in the second quarter. Private Capital Group LLC now owns 340 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 163 shares in the last quarter. Pearl River Capital LLC bought a new position in shares of Masimo in the second quarter valued at approximately $37,000. Finally, NEXT Financial Group Inc grew its holdings in shares of Masimo by 172.0% in the second quarter. NEXT Financial Group Inc now owns 544 shares of the medical equipment provider’s stock valued at $81,000 after acquiring an additional 344 shares in the last quarter. 83.08% of the stock is owned by institutional investors.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.